← Back

Shanghai Pharmaceuticals Holding Co Ltd

Shanghai Pharmaceuticals Holding Co., Ltd. researches, develops, manufactures, and sells pharmaceutical and healthcare products in China and internationally. It operates through four segments: Production, Distribution, Retail, and Others. The company offers chemical and biological drugs, Chinese medicine, health care products, and medical devices for areas such as immunology, psychiatric and neurological conditions, tumors, cardiovascular and digestive metabolism, respiratory system, and anti-infection diseases. It also provides pharmaceutical distribution, warehousing, logistics, and other value-added supply chain solutions to manufacturers, hospitals, distributors, and retail pharmacies, and operates a network of retail pharmacy stores. Incorporated in 1994, it is headquartered in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 2607.HK
Biotech & Genomic Medicine▲

Shanghai Pharmaceuticals Receives Production Approval for Ruxolitinib Phosphate Tablets

Shanghai Pharmaceuticals announced that its subsidiary Changzhou Pharmaceutical Factory has received a drug registration certificate for Ruxolitinib Phosphate Tablets from the National Medical Products Administration, with specifications of 5 mg, 15 mg, and 20 mg, classified as a Category 4 chemical drug. The drug is used to treat adult patients with intermediate or high-risk primary myelofibrosis and other myelofibrosis conditions, as well as graft-versus-host disease in patients aged 12 and older. It was jointly developed by Incyte and Novartis and launched in the United States in 2011. Changzhou Pharmaceutical Factory submitted its registration and marketing application in December 2024, with cumulative research and development investment of approximately 24.81 million yuan.
601607.CG ▲
Biotech & Genomic Medicine
Jiemian·19dRead more →
2607.HK▼

Shanghai Pharmaceuticals' 2026 interim net profit was 3.504 billion yuan, down 21.40% year-on-year

Shanghai Pharmaceuticals released its 2026 interim report. Total operating revenue was 147.47 billion yuan, up 4.15% year-on-year, while net profit attributable to the parent company was 3.504 billion yuan, down 21.40% year-on-year. Net cash inflow from operating activities was 4.45 billion yuan, up 349.78% year-on-year. The company's asset-liability ratio was 61.46%, gross margin was 11.03%, ROE was 4.47%, and diluted earnings per share was 0.95 yuan. The number of shareholders was 95,300, and the top ten shareholders held 90.50% of the shares.
601607.CG ▼
Jiemian·22dRead more →
2607.HK▲

Shanghai Pharmaceuticals' Omeprazole and Sodium Bicarbonate for Oral Suspension (I) Approved for Production

Shanghai Pharmaceuticals' subsidiary SPH Sine has received a drug registration certificate from the National Medical Products Administration for Omeprazole and Sodium Bicarbonate for Oral Suspension (I), granting approval for production. The drug is primarily used for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease. Shanghai Pharmaceuticals stated that the approval will help expand its market share, but sales remain uncertain due to policy and market conditions, and reminded investors to be aware of the risks.
601607.CG ▲
Jiemian·47dRead more →
2607.HK▲

Shanghai Pharma's Three Longhu Products Receive Canadian Product Licences

Shanghai Pharma announced that three products from its subsidiary Shangyao Zhonghua — Longhu Cooling Oil Classic, Longhu Cooling Oil Extra Strength, and Longhu Roll-on Essential Oil — received product licences from Health Canada on 30 July 2026. The licences are for the temporary relief of muscle and joint aches or discomfort. The company submitted the registration applications in May 2026, with cumulative registration expenses of approximately 49,500 yuan. Shanghai Pharma stated that this approval is positive for expanding overseas markets, but export business is subject to uncertainties from factors such as overseas regulations, market conditions, and exchange rate fluctuations.
601607.CG ▲
Jiemian·51dRead more →
© 2026 MarketDXAsset